AstraZeneca Annual Report and 142 Form 20-F Information 2005 NOTES TO THE FINANCIAL STATEMENTS 1 FIXED ASSET INVESTMENTS Investments in subsidiaries Shares Loans Total $m $m $m Cost at beginning of year 6,715 24,197 30,912 Additions Repayment of loan 6,056 6,056 Net book value at 31 December 2005 6,715 18,141 24,856 Net book value at 31 December 2004 6,715 24,197 30,912 2 OTHER DEBTORS 2005 2004 $m $m Other debtors 10 Deferred tax asset 17 25 27 25 3 NON-TRADE CREDITORS 2004 2005 restated $m $m Amounts due within one year Short term borrowings unsecured 5 4 Other creditors 5 116 Amounts owed to subsidiaries 10 2,409 20 2,529 4LOANS Repayment 2005 2004 dates $m $m Loans owed to subsidiaries unsecured US dollars 7.2% loan 2023 283 283 Loans external unsecured US dollars 5.4% callable bond 2014 747 747 1,030 1,030 Loans or instalments thereof are repayable: After five years from balance sheet date 1,030 1,030 From two to five years From one to two years Total unsecured 1,030 1,030 Total due within one year 1,030 1,030 The fair values of the external loans and the loans owed to subsidiaries are as follows: 2005 2004 $m $m 7.2% loan 341 338 5.4% callable bond 770 789 1,111 1,127 Both loans are at fixed interest rates.
Accordingly the fair values of the loans will change as market rates change.
However, since the loans are held at amortised cost, changes in interest rates and the credit rating of the Company will not have an effect on the Companys net assets.
